3/29/2013 9:08:39 AM
WHEAT RIDGE, Colo.--(BUSINESS WIRE)--Positive clinical outcomes continue to be reported by researchers worldwide with transcatheter aortic valve implantation (TAVI). Moreover, new technologies are in development and will, in the future, offer additional minimally invasive treatment options for diseased aortic and mitral valves in patients ineligible for surgery. To assist with the research and development of these new technologies, BDC Laboratories provides innovative and advanced product offerings to support medical device companies in evaluating their next-generation implants.
comments powered by